Pfizer’s Dividend Under Scrutiny: Navigating a Shifting Landscape Amidst Patent Expirations and Pipeline Development
Pfizer (NYSE: PFE), a pharmaceutical titan, currently finds itself in a period of significant transition, reflected in its stock performance, which has declined by over 50% from its 2021 peak.…
